- Home
- Applications
- senegal
- bowel disease
Bowel Disease Product Applications Available In Senegal
5 applications found
A defective gastrointestinal (GI) barrier is associated with multiple conditions of high unmet need, including inflammatory bowel disease, chemotherapy-induced gut injury, food allergies, and celiac disease. We are advancing novel, oral, non-immunosuppressive therapeutics to improve GI barrier function. Our multi-targeted approach involves improving epithelial cell homeostasis, restoring appropriate immune responses, and repairing secretory cell ...
ByKallyope Inc. based in New York City, NEW YORK (USA)
An estimated 20 million people in the U.S. struggle with bowel incontinence, and an estimated 80% suffer in silence. Secca therapy is a safe, effective, minimally invasive procedure to treat bowel incontinence. Secca therapy is an innovative treatment option for patients with BCD, who have not responded to conservative treatments and would like to avoid invasive surgery or implants. ...
ByRestech based in Houston, TEXAS (USA)
Longitudinal imaging of pancreatic cancer. Monitor in a minimally invasive manner both tissue morphology and fibrosis (fluorescein) and cathepsin activity (Prosense® 680). A very thin probe (S 650) was used to monitor the pancreas of the same mouse over 9 months. ...
ByMauna Kea Technologies based in Paris, FRANCE
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of ...
ByFinch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA)
Inflammatory bowel disease (IBD), largely comprising the two conditions, Crohn’s Disease and Ulcerative Colitis, is now emerging as a global health problem. It now affects about 6 million people in Europe and US, comprising up to 620,000 in the UK (IBD Standards UK, 2013 Update). The symptoms of diarrhoea, abdominal pain and bloody stool substantially affect the quality of life of sufferers, and complications can be life threatening. IBD is also strongly associated with colorectal cancer development risk. ...
ByDiagNodus Ltd. based in Cambridge, UNITED KINGDOM